[8-K] ADC Therapeutics SA Reports Material Event
ADC Therapeutics SA reported that it issued a press release announcing its financial results for the second quarter ended June 30, 2025. The company filed a Current Report on Form 8-K to attach that press release as Exhibit 99.1, and the filing also includes a Cover Page Interactive Data File as Exhibit 104.
The filing states that the information in Item 2.02 and Exhibit 99.1 is incorporated by reference but shall not be deemed "filed" for purposes of Section 18 of the Exchange Act. The report is signed on behalf of the company by Jose Carmona, Chief Financial Officer. The 8-K itself does not include the detailed financial tables or results within the body of the filing.
ADC Therapeutics SA ha diffuso un comunicato stampa con i risultati finanziari per il secondo trimestre chiuso il 30 giugno 2025. La societ脿 ha depositato un Current Report sul Formulario 8-K allegando quel comunicato come Exhibit 99.1, e la segnalazione include inoltre un Cover Page Interactive Data File come Exhibit 104.
Nel deposito si precisa che le informazioni contenute nell'Item 2.02 e nell'Exhibit 99.1 sono incorporate per riferimento ma non devono essere considerate "filed" ai fini della Sezione 18 dell'Exchange Act. Il rapporto 猫 firmato per conto della societ脿 da Jose Carmona, Chief Financial Officer. L'8-K stesso non contiene tabelle finanziarie dettagliate n茅 i risultati all'interno del corpo della segnalazione.
ADC Therapeutics SA public贸 un comunicado de prensa con sus resultados financieros del segundo trimestre cerrado el 30 de junio de 2025. La compa帽铆a present贸 un Current Report on Form 8-K adjuntando ese comunicado como Exhibit 99.1, y la presentaci贸n incluye adem谩s un Cover Page Interactive Data File como Exhibit 104.
La presentaci贸n indica que la informaci贸n del Item 2.02 y del Exhibit 99.1 se incorpora por referencia pero no deber谩 considerarse "filed" a efectos de la Secci贸n 18 del Exchange Act. El informe est谩 firmado en nombre de la compa帽铆a por Jose Carmona, Chief Financial Officer. El 8-K en s铆 no incluye en su cuerpo las tablas financieras detalladas ni los resultados.
ADC Therapeutics SA電� 2025雲� 6鞗� 30鞚�搿� 膦呺霅� 2攵勱赴 鞛鞁れ爜鞚� 氚滍憸頃橂姅 氤措弰鞛愲毳� 氚绊彫頄堧嫟瓿� 氤搓碃頄堨姷雼堧嫟. 須岇偓電� 頃措嫻 氤措弰鞛愲毳� Exhibit 99.1搿� 觳秬頃橃棳 Current Report on Form 8-K毳� 鞝滌稖頄堨溂氅�, 鞝滌稖靹滊鞐愲姅 Cover Page Interactive Data File鞚� Exhibit 104搿� 韽暔霅橃柎 鞛堨姷雼堧嫟.
鞝滌稖靹滊鞐愲姅 Item 2.02鞕� Exhibit 99.1鞚� 鞝曤炒臧� 彀胳“搿� 韱淀暕霅橃毵� Exchange Act鞚� Section 18 氇╈爜靸� "filed"搿� 臧勳＜霅橃 鞎婋姅雼�瓿� 氇呾嫓霅橃柎 鞛堨姷雼堧嫟. 氤搓碃靹滊姅 Jose Carmona, Chief Financial Officer臧� 須岇偓毳� 雽�響滍晿鞐� 靹滊獏頄堨姷雼堧嫟. 頃措嫻 8-K 氤鸽鞐愲姅 靸侅劯頃� 鞛響滊倶 瓴瓣臣臧� 韽暔霅橃柎 鞛堨 鞎婌姷雼堧嫟.
ADC Therapeutics SA a indiqu茅 avoir publi茅 un communiqu茅 pr茅sentant ses r茅sultats financiers pour le deuxi猫me trimestre clos le 30 juin 2025. La soci茅t茅 a d茅pos茅 un Current Report on Form 8鈥慘 en joignant ce communiqu茅 en tant que Exhibit 99.1, et le d茅p么t comprend 茅galement un Cover Page Interactive Data File en tant qu'Exhibit 104.
Le d茅p么t pr茅cise que les informations figurant 脿 l'Item 2.02 et dans l'Exhibit 99.1 sont incorpor茅es par renvoi mais ne doivent pas 锚tre r茅put茅es 芦 filed 禄 aux fins de la Section 18 de l'Exchange Act. Le rapport est sign茅 au nom de la soci茅t茅 par Jose Carmona, Chief Financial Officer. Le formulaire 8鈥慘 lui鈥憁锚me n'inclut pas, dans son corps, les tableaux financiers d茅taill茅s ni les r茅sultats.
ADC Therapeutics SA teilte mit, dass es eine Pressemitteilung zu den Finanzergebnissen f眉r das zweite Quartal zum 30. Juni 2025 herausgegeben hat. Das Unternehmen reichte einen Current Report on Form 8鈥慘 ein und f眉gte diese Pressemitteilung als Exhibit 99.1 bei; au脽erdem enth盲lt die Einreichung eine Cover Page Interactive Data File als Exhibit 104.
In der Einreichung hei脽t es, dass die Informationen in Item 2.02 und in Exhibit 99.1 durch Verweis aufgenommen werden, aber f眉r Zwecke von Section 18 des Exchange Act nicht als "filed" gelten sollen. Der Bericht ist im Namen des Unternehmens von Jose Carmona, Chief Financial Officer unterzeichnet. Der 8鈥慘 selbst enth盲lt im Text keine detaillierten Finanztabellen oder Ergebnisse.
- The company attached a press release announcing financial results for the quarter ended June 30, 2025 as Exhibit 99.1 to the 8-K.
- The filing includes an interactive Cover Page XBRL file as Exhibit 104, indicating structured data is provided.
- The Form 8-K does not include the actual financial results within the filing text; substantive numbers must be obtained from Exhibit 99.1.
- The registrant explicitly states that Item 2.02 and Exhibit 99.1 shall not be deemed "filed" for purposes of Section 18 of the Exchange Act, limiting Section 18 liability.
Insights
TL;DR: ADC attached its Q2 2025 results press release to an 8-K; the release is disclosed but not legally "filed" under Section 18.
The 8-K is a routine disclosure mechanism to ensure the market has access to the company鈥檚 Q2 2025 results via Exhibit 99.1. Because the company explicitly states the press release is not "filed" under Section 18, investors should treat the exhibit as furnished disclosure rather than a filing that creates Section 18 liabilities. The document provides no numeric results in the 8-K text itself, so stakeholders must review Exhibit 99.1 for the substantive financial metrics.
TL;DR: This 8-K reflects standard disclosure practice and reiterates legal limits on liability for the attached press release.
The Form 8-K attaches a press release as Exhibit 99.1 and includes customary boilerplate that the exhibit is not "filed" under the Exchange Act. The filing establishes a public record of the release and is signed by the CFO, reflecting compliance with disclosure procedures. There are no governance changes, officer departures, or material transactions reported in this filing.
ADC Therapeutics SA ha diffuso un comunicato stampa con i risultati finanziari per il secondo trimestre chiuso il 30 giugno 2025. La societ脿 ha depositato un Current Report sul Formulario 8-K allegando quel comunicato come Exhibit 99.1, e la segnalazione include inoltre un Cover Page Interactive Data File come Exhibit 104.
Nel deposito si precisa che le informazioni contenute nell'Item 2.02 e nell'Exhibit 99.1 sono incorporate per riferimento ma non devono essere considerate "filed" ai fini della Sezione 18 dell'Exchange Act. Il rapporto 猫 firmato per conto della societ脿 da Jose Carmona, Chief Financial Officer. L'8-K stesso non contiene tabelle finanziarie dettagliate n茅 i risultati all'interno del corpo della segnalazione.
ADC Therapeutics SA public贸 un comunicado de prensa con sus resultados financieros del segundo trimestre cerrado el 30 de junio de 2025. La compa帽铆a present贸 un Current Report on Form 8-K adjuntando ese comunicado como Exhibit 99.1, y la presentaci贸n incluye adem谩s un Cover Page Interactive Data File como Exhibit 104.
La presentaci贸n indica que la informaci贸n del Item 2.02 y del Exhibit 99.1 se incorpora por referencia pero no deber谩 considerarse "filed" a efectos de la Secci贸n 18 del Exchange Act. El informe est谩 firmado en nombre de la compa帽铆a por Jose Carmona, Chief Financial Officer. El 8-K en s铆 no incluye en su cuerpo las tablas financieras detalladas ni los resultados.
ADC Therapeutics SA電� 2025雲� 6鞗� 30鞚�搿� 膦呺霅� 2攵勱赴 鞛鞁れ爜鞚� 氚滍憸頃橂姅 氤措弰鞛愲毳� 氚绊彫頄堧嫟瓿� 氤搓碃頄堨姷雼堧嫟. 須岇偓電� 頃措嫻 氤措弰鞛愲毳� Exhibit 99.1搿� 觳秬頃橃棳 Current Report on Form 8-K毳� 鞝滌稖頄堨溂氅�, 鞝滌稖靹滊鞐愲姅 Cover Page Interactive Data File鞚� Exhibit 104搿� 韽暔霅橃柎 鞛堨姷雼堧嫟.
鞝滌稖靹滊鞐愲姅 Item 2.02鞕� Exhibit 99.1鞚� 鞝曤炒臧� 彀胳“搿� 韱淀暕霅橃毵� Exchange Act鞚� Section 18 氇╈爜靸� "filed"搿� 臧勳＜霅橃 鞎婋姅雼�瓿� 氇呾嫓霅橃柎 鞛堨姷雼堧嫟. 氤搓碃靹滊姅 Jose Carmona, Chief Financial Officer臧� 須岇偓毳� 雽�響滍晿鞐� 靹滊獏頄堨姷雼堧嫟. 頃措嫻 8-K 氤鸽鞐愲姅 靸侅劯頃� 鞛響滊倶 瓴瓣臣臧� 韽暔霅橃柎 鞛堨 鞎婌姷雼堧嫟.
ADC Therapeutics SA a indiqu茅 avoir publi茅 un communiqu茅 pr茅sentant ses r茅sultats financiers pour le deuxi猫me trimestre clos le 30 juin 2025. La soci茅t茅 a d茅pos茅 un Current Report on Form 8鈥慘 en joignant ce communiqu茅 en tant que Exhibit 99.1, et le d茅p么t comprend 茅galement un Cover Page Interactive Data File en tant qu'Exhibit 104.
Le d茅p么t pr茅cise que les informations figurant 脿 l'Item 2.02 et dans l'Exhibit 99.1 sont incorpor茅es par renvoi mais ne doivent pas 锚tre r茅put茅es 芦 filed 禄 aux fins de la Section 18 de l'Exchange Act. Le rapport est sign茅 au nom de la soci茅t茅 par Jose Carmona, Chief Financial Officer. Le formulaire 8鈥慘 lui鈥憁锚me n'inclut pas, dans son corps, les tableaux financiers d茅taill茅s ni les r茅sultats.
ADC Therapeutics SA teilte mit, dass es eine Pressemitteilung zu den Finanzergebnissen f眉r das zweite Quartal zum 30. Juni 2025 herausgegeben hat. Das Unternehmen reichte einen Current Report on Form 8鈥慘 ein und f眉gte diese Pressemitteilung als Exhibit 99.1 bei; au脽erdem enth盲lt die Einreichung eine Cover Page Interactive Data File als Exhibit 104.
In der Einreichung hei脽t es, dass die Informationen in Item 2.02 und in Exhibit 99.1 durch Verweis aufgenommen werden, aber f眉r Zwecke von Section 18 des Exchange Act nicht als "filed" gelten sollen. Der Bericht ist im Namen des Unternehmens von Jose Carmona, Chief Financial Officer unterzeichnet. Der 8鈥慘 selbst enth盲lt im Text keine detaillierten Finanztabellen oder Ergebnisse.
FAQ
What did ADC Therapeutics (ADCT) disclose in this 8-K?
Is the press release attached to ADCT's 8-K considered "filed"?
Where can investors find the detailed Q2 2025 results for ADCT?
On which exchange are ADC Therapeutics' common shares listed?
What is ADC Therapeutics' jurisdiction of incorporation?
Who signed the 8-K on behalf of ADC Therapeutics?
